Neutralization of S100A4 induces stabilization of atherosclerotic plaques: role of smooth muscle cells

Cardiovasc Res. 2022 Jan 7;118(1):141-155. doi: 10.1093/cvr/cvaa311.

Abstract

Aims: During atherosclerosis, smooth muscle cells (SMCs) accumulate in the intima where they switch from a contractile to a synthetic phenotype. From porcine coronary artery, we isolated spindle-shaped (S) SMCs exhibiting features of the contractile phenotype and rhomboid (R) SMCs typical of the synthetic phenotype. S100A4 was identified as a marker of R-SMCs in vitro and intimal SMCs, in pig and man. S100A4 exhibits intra- and extracellular functions. In this study, we investigated the role of extracellular S100A4 in SMC phenotypic transition.

Methods and results: S-SMCs were treated with oligomeric recombinant S100A4 (oS100A4), which induced nuclear factor (NF)-κB activation. Treatment of S-SMCs with oS100A4 in combination with platelet-derived growth factor (PDGF)-BB induced a complete SMC transition towards a pro-inflammatory R-phenotype associated with NF-κB activation, through toll-like receptor-4. RNA sequencing of cells treated with oS100A4/PDGF-BB revealed a strong up-regulation of pro-inflammatory genes and enrichment of transcription factor binding sites essential for SMC phenotypic transition. In a mouse model of established atherosclerosis, neutralization of extracellular S100A4 decreased area of atherosclerotic lesions, necrotic core, and CD68 expression and increased α-smooth muscle actin and smooth muscle myosin heavy chain expression.

Conclusion: We suggest that the neutralization of extracellular S100A4 promotes the stabilization of atherosclerotic plaques. Extracellular S100A4 could be a new target to influence the evolution of atherosclerotic plaques.

Keywords: ApoE−/−; CD68; Extracellular S100A4; NF-κB; RAGE; Smooth muscle myosin heavy chains; TLR4; α-Smooth muscle actin.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Actins / metabolism
  • Animals
  • Antibodies, Neutralizing / pharmacology*
  • Antigens, CD / metabolism
  • Antigens, Differentiation, Myelomonocytic / metabolism
  • Aorta / drug effects
  • Aorta / metabolism
  • Aorta / pathology
  • Aortic Diseases / drug therapy*
  • Aortic Diseases / genetics
  • Aortic Diseases / metabolism
  • Aortic Diseases / pathology
  • Atherosclerosis / drug therapy*
  • Atherosclerosis / genetics
  • Atherosclerosis / metabolism
  • Atherosclerosis / pathology
  • Becaplermin / pharmacology
  • Cells, Cultured
  • Disease Models, Animal
  • Humans
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout, ApoE
  • Muscle, Smooth, Vascular / drug effects*
  • Muscle, Smooth, Vascular / metabolism
  • Muscle, Smooth, Vascular / pathology
  • Myocytes, Smooth Muscle / drug effects*
  • Myocytes, Smooth Muscle / metabolism
  • Myocytes, Smooth Muscle / pathology
  • Myosin Heavy Chains / metabolism
  • Phenotype
  • Plaque, Atherosclerotic*
  • S100 Calcium-Binding Protein A4 / antagonists & inhibitors*
  • S100 Calcium-Binding Protein A4 / metabolism
  • S100 Calcium-Binding Protein A4 / pharmacology
  • Signal Transduction
  • Smooth Muscle Myosins / metabolism
  • Sus scrofa
  • Toll-Like Receptor 4 / metabolism

Substances

  • Actins
  • Antibodies, Neutralizing
  • Antigens, CD
  • Antigens, Differentiation, Myelomonocytic
  • CD68 antigen, human
  • S100 Calcium-Binding Protein A4
  • S100a4 protein, mouse
  • Toll-Like Receptor 4
  • S100A4 protein, human
  • Becaplermin
  • Smooth Muscle Myosins
  • Myosin Heavy Chains